Abstracts tagged "fractures"

Abstract Number: 1027 • 2016 ACR/ARHP Annual Meeting
Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
Michael R. McClung¹, Bente Langdahl², Socrates Papapoulos³, Kenneth G. Saag⁴, Henry Bone⁵, Douglas P. Kiel⁶, Kurt Lippuner⁷, Toshitaka Nakamura⁸, Ian Reid⁹, Norman Heyden¹⁰, Carolyn DaSilva¹⁰, Boyd B. Scott¹⁰, Rachid Massaad¹¹, Keith D. Kaufman¹⁰, S. Aubrey Stoch¹⁰, Arthur Santora¹⁰, Deborah Gurner¹⁰ and Antonio Lombardi¹⁰, ¹Oregon Osteoporosis Center, Portland, OR, USA, Portland, OR, ²Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ³Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Michigan Bone & Mineral Clinic, Detroit, MI, USA and The Osteoporosis Center at St. Luke's Hospital, Chesterfield, MO, USA, Detroit, MI, ⁶Institute for Aging Research, Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷Bern University Hospital, Bern, Switzerland, Bern, Switzerland, ⁸University of Occupational and Environmental Health, Fukuoka, Japan, Fukuoaka, Japan, ⁹University of Auckland, Auckland, New Zealand, Auckland, New Zealand, ¹⁰Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ¹¹MSD Europe Inc., Brussels, Belgium, Brussels, Belgium
Background/Purpose: Long-Term Odanacatib Fracture Trial [Women 65 years of age with BMD T-score ≤–2.5 at total hip (TH) or femoral neck (FN), or with radiographic…
Abstract Number: 1028 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension
Jacques P Brown¹, S Ferrari², N Gilchrist³, Jens-Erik Beck Jensen⁴, N Pannacciulli⁵, Chris Recknor⁶, Christian Roux⁷, Shawna Smith⁵, Ove Törring⁸, Ivo Valter⁹, Rachel B Wagman⁵, A Wang⁵ and SR Cummings¹⁰, ¹Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³The Princess Margaret Hospital, Christchurch, New Zealand, ⁴Hvidovre University Hospital, Hvidovre, Denmark, ⁵Amgen Inc., Thousand Oaks, CA, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Paris Descartes University, Paris, France, ⁸Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, ⁹Center for Clinical and Basic Research, Tallinn, Estonia, ¹⁰SFCC, CPMC Research Institute & UCSF, San Francisco, CA
Background/Purpose: Denosumab (DMAb) treatment has been shown to decrease fracture (Fx) risk. Unlike bisphosphonates, DMAb is a monoclonal antibody against RANKL. Discontinuation is characterized by…
Abstract Number: 1223 • 2016 ACR/ARHP Annual Meeting
The Cost of Confronting Osteoporosis:Cost Study of a Fracture Liaison Service
Gabor Major^1,2, Rod Ling^3,4, Andrew Searles^3,4, Fiona Niddrie⁵, Ayano Nakayama⁶, Elizabeth Holliday^4,7, John Attia^4,7 and Nikolai Bogduk^4,6, ¹Rheumatology, Bone and Joint Institute, John Hunter Hospital NSW Australia, Newcastle, Australia, ²Medicine, University of Newcastle, Newcastle, Australia, ³Health Economics, Hunter Medical Research Institute, Newcastle, Australia, ⁴University of Newcastle, Newcastle, Australia, ⁵Rheumatology, Bone and Joint Institute,John Hunter Hospital, Newcatle, Australia, ⁶Rheumatology, Bone and Joint Institute,John Hunter Hospital, Newcastle, Australia, ⁷Hunter Medical Research Institute, Newcastle, Australia
Background/Purpose: Services that actively seek out and identify patients with fractures following a minimal trauma injury have been promoted as the most effective means of…
Abstract Number: 1232 • 2016 ACR/ARHP Annual Meeting
Interdisciplinary Osteoporosis Clinical Working Group and Fracture Liaison Service at Loma Linda University Medical Center (LLUMC): Laying the Groundwork
Karina Marianne D. Torralba¹, Micah Yu², Cong-Bin Wang³, Kevin A. Codorniz⁴, James P. Larsen³, Silvana M Giannelli⁵, Vaneet Sandhu⁶, Nasim Daoud⁷ and Gary D. Botimer³, ¹Rheumatology, Loma Linda University, Loma Linda, CA, ²Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, ³Loma Linda University Medical Center, Loma Linda, CA, ⁴Loma Linda University University Medical Center, Loma Linda, CA, ⁵Division of Endocrinology, Loma Linda University, Loma Linda, CA, ⁶Division of Rheumatology, Loma Linda University, Loma Linda, CA, ⁷Division of Rheumatology, Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: There is an ongoing effort worldwide to effect quality improvement to address secondary prevention of fractures. Patients who have incurred fractures attributed to osteoporosis…
Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting
Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women
Denise Boudreau¹, Onchee Yu¹, Akhila Balasubramanian², Jane Grafton¹, Heidi Wirtz³, Andreas Grauer³, D. Barry Crittenden³ and Delia Scholes¹, ¹Group Health Research Institute, Seattle, WA, ²Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…
Abstract Number: 2084 • 2015 ACR/ARHP Annual Meeting
Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Modulates Bone Resorption in Inflammatory Arthritis and Fracture Repair
Yahui Grace Chiu¹, Tzong-Ren Sheu², Jinbo Li³, Dongge Li⁴, Michael Thullen², Brendan Boyce⁵, Christopher T. Ritchlin⁶ and Javier Rangel-Moreno⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵University of Rochester, Rochester, NY, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁷Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Osteoclasts (OC) direct pathologic bone resorption in osteoporosis and inflammatory arthritis. We previously demonstrated that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a 7-pass transmembrane protein,…
Abstract Number: 382 • 2015 ACR/ARHP Annual Meeting
Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?
Christoph Hemmeler¹, Sabrina Morell², Paul Hasler¹ and Thomas Gross², ¹Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ²Traumatology, Kantonsspital Aarau, Aarau, Switzerland
Background/Purpose: Evidence shows that of ten patients taking medication against osteoporosis one will avoid subsequent fractures, decreasing the risk by > 50 %. On the…
Abstract Number: 371 • 2015 ACR/ARHP Annual Meeting
New Vertebral Fractures after Vertebroplasty: Two Year Results from a Randomised Placebo-Controlled Trial
Margaret P. Staples¹, B Matthew Howe², Michael Ringler², Peter Mitchell³, Chris Wriedt⁴, John Wark⁵, Peter Ebeling⁶, Richard Osborne⁷, David Kallmes² and Rachelle Buchbinder⁸, ¹Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Malvern, Australia, ²Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN, ³Department of Radiology, The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, ⁴MIA Radiology, Melbourne, Australia, ⁵Department of Medicine, The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia, ⁶Department of Medicine, Monash University, Monash Medical Centre, Melbourne, Australia, ⁷Public Health Innovation, Deakin University, Melbourne, Australia, ⁸Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia
Background/Purpose: We previously reported the results of a randomized participant and outcome assessor blinded controlled trial that found no beneficial effect of vertebroplasty (VP) over…
Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Sizheng Zhao^1,2, Barbara Hauser³, Micaela Visconti³, Philip L. Riches³, Stuart H. Ralston³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ²Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ³Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…
Abstract Number: 3173 • 2015 ACR/ARHP Annual Meeting
Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men
Lyn March¹, Weiwen Chen², Judy M Simpson³, Fiona Blyth⁴ and Jacqueline Center², ¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Endocrinology, Osteoporosis & Bone Biology Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Darlinghurst, Australia, ³Statistics, University of Sydney School of Public Health, Sydney, Australia, ⁴Concord Clinical School University of Sydney and Sax Institute, Sydney, Australia
Background/Purpose: Osteoporotic (OP) fractures and falls are a growing global problem as the population ages. One third of all falls related deaths are attributable to…
Abstract Number: 2210 • 2015 ACR/ARHP Annual Meeting
Immunological Dysregulation and Inadequate Hypoxia Adaptation – HIF-Stabilization As Possible Prevention of Fracture Healing Disorders in RA or Immune-Suppressed Patients
Annemarie Lang^1,2,3, Sarah Fuegener², Paula Hoff^1,2, Katharina Schmidt-Bleek⁴, Timo Gaber^1,2 and Frank Buttgereit², ¹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ⁴Julius Wolff Institut, Charité University Medicine, Berlin, Germany
Background/Purpose: Patients suffering from rheumatoid arthritis (RA) are often affected by fracture-healing complications such as increased fracture healing time or non-unions. There is not much…
Abstract Number: 2471 • 2014 ACR/ARHP Annual Meeting
Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis
Robin Dore¹, Kenneth G. Saag², Guillermo Valenzuela³, Kathleen Taylor⁴, Qiu He⁴, Jahangir Alam⁴ and Kelly D. Krohn⁵, ¹University of California, Los Angeles, CA, ²Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ³Integral Rheumatology and Immunology Specialists, Plantation, FL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵DC 5208, Eli Lilly and Company, LLC, Indianapolis, Indiana, Indianapolis, IN
Background/Purpose: A common complication in rheumatoid arthritis (RA) is osteoporosis (OP) with increased incidence of fragility fractures. RA is the only disease specifically included…
Abstract Number: 2268 • 2014 ACR/ARHP Annual Meeting
Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial
Michael R. McClung¹, Bente Langdahl², Socrates Papapoulos³, Kenneth G. Saag⁴, Silvano Adami⁵, Henry G. Bone⁶, Tobias de Villiers⁷, Douglas P. Kiel⁸, Annie Kung⁹, Prasanna Kumar¹⁰, Sung-Kil Lim¹¹, Xu Ling¹², Kurt Lippuner¹³, Carlos Mautalen¹⁴, Toshitaka Nakamura¹⁵, Jean-Yves Reginster¹⁶, Ian R. Reid¹⁷, José Adolfo Rodríguez-Portales¹⁸, Christian Roux¹⁹, Jesus Walliser²⁰, Nelson B. Watts²¹, José R. Zanchetta²², Cristiano A.F. Zerbini²³, Andrea Rybak-Feiglin²⁴, Dosinda Cohn²⁴, Carolyn A. DaSilva²⁴, Rachid Massaad²⁵, Arthur Santora²⁴, Boyd B. Scott²⁴, Nadia Verbruggen²⁵, Albert Leung²⁶ and Antonio Lombardi²⁴, ¹Oregon Osteoporosis Center, Portland, OR, ²Aarhus University Hospital, Aarhus, Denmark, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Department, University of Verona, Verona, Italy, ⁶Michigan Bone and Mineral Clinic, Detroit, MI, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, ⁹University of Hong Kong, Pokfulam, Hong Kong, China, ¹⁰Bangalore Diabetes Centre, Bangalore, India, ¹¹Yonsei University, Seoul, South Korea, ¹²Peking Union Medical College Hospital, Beijing, China, ¹³Bern University Hospital, Bern, Switzerland, ¹⁴Centro de Osteopatías Médicas, Buenos Aires, Argentina, ¹⁵University of Occupational & Environmental Health, Fukuoaka, Japan, ¹⁶CHU-Centre Ville, Policliniques BRULL, Liege, Belgium, ¹⁷Department of Medicine, University of Auckland, Auckland, New Zealand, ¹⁸Pontificia Universidad Católica de Chile, Santiago, Chile, ¹⁹Paris Descartes University, Cochin Hospital, Paris, France, ²⁰Bone Metabolism Clinic, Hospital Angeles del Pedregal, Mexico City, Mexico, ²¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²²IDIM Instituto de Investigaciones Metabolicas, Buenos Aires, Argentina, ²³Centro Paulista de Investigações Clinicas, São Paulo, Brazil, ²⁴Merck Sharp and Dohme Corp., Rahway, NJ, ²⁵MSD Europe Inc., Brussels, Belgium, ²⁶Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. The Phase III Long-Term Odanacatib Fracture Trial…
Abstract Number: 2106 • 2014 ACR/ARHP Annual Meeting
Surgical Compared with Nonsurgical Management of Fractures in Men with Chronic Spinal Cord Injury
Monique Bethel¹, Lauren Bailey², Frances Weaver², Brian Le³, Stephen Burns⁴, Jelena Svircev⁴, Michael Heggeness⁵ and Laura Carbone⁶, ¹Internal Medicine, Georgia Regents University, Augusta, GA, ²Edward Hines Jr. VA Hospital, Chicago, IL, ³Medicine, Georgia Regents University, Augusta, GA, ⁴VA Puget Sound Healthcare System, Seattle, WA, ⁵Orthopaedic Surgery, University of Kansas School of Medicine, Kansas City, KS, ⁶Medicine, Charlie Norwood VA Medical Center, Augusta, GA
Background/Purpose: Patients with a chronic spinal cord injury (SCI) develop osteoporosis and are at high risk for fracture. However, there is limited information on how…
Abstract Number: 1835 • 2014 ACR/ARHP Annual Meeting
Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture
Robert A. Overman¹ and Chad L. Deal², ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Current National Osteoporosis Guidelines recommend treatment with an approved osteoporosis medication after hip and vertebral fracture. Only 20% of patients receive osteoporosis therapy after…